Good morning from Fast Company. Here's our daily look into what’s driving today’s creative business leaders. Going public was in 23andMe‘s genes. Now, it’s happening. The consumer genetics and research company announced Thursday that it will soon be traded on the New York Stock Exchange, thanks to a merger with a special purpose acquisition company created by Richard Branson‘s Virgin Group. The deal, worth an estimated $3.